OncoMatch

OncoMatch/Clinical Trials/NCT03099356

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Is NCT03099356 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cyclophosphamide and Sirolimus for metastatic thyroid cancer.

Phase 2RecruitingUniversity of Michigan Rogel Cancer CenterNCT03099356Data as of May 2026

Treatment: Cyclophosphamide · SirolimusThis study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.

Check if I qualify

Extracted eligibility criteria

Cancer type

Thyroid Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: radioiodine (Iodine-131)

Previous failure of Iodine-131 (131I) therapy or not candidates to receive 131I as assessed by treating physician.

Cannot have received: radioiodine (Iodine-131)

Exception: 4 weeks if negative post-treatment scan

131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)

Cannot have received: chemotherapy

Chemotherapy...within 4 weeks

Cannot have received: tyrosine kinase inhibitor

tyrosine kinase inhibitor...within 4 weeks

Cannot have received: radiation therapy

radiation therapy within 4 weeks

Cannot have received: experimental therapy

Prior experimental therapy within 4 weeks of planned start of this trial

Cannot have received: mTOR inhibitor

Previous treatment with an mTOR inhibitor

Lab requirements

Blood counts

Adequate organ and marrow function

Kidney function

Adequate organ and marrow function

Liver function

Adequate organ and marrow function

Adequate organ and marrow function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Michigan Cancer Center · Ann Arbor, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify